DUOX1 and lung cancer: Moreover, although EGFR inhibitors are typically not recommended for use in treatment of lung cancers expressing wild-type EGFR, some patients with wild-type EGFR may also benefit, and identification of biomarkers to identify such patients would be desirable.45 In this regard, our studies suggest that lung cancers with wild-type EGFR and positive DUOX1 expression may benefit for EGFR inhibitor therapy.